Stocks › ABT
Abbott Laboratories (ABT) stock analysis
WEAK BUY 18% confidence · analysed Oct 29, 2026
On Oct 29, 2026, our model rated Abbott Laboratories (ABT) WEAK BUY with 18% confidence at a price of $102.64. That means the signals lean positive, but they are mixed, so conviction is low.
Technical picture
The 14-day RSI is 63, showing healthy upward momentum without being stretched.
MACD is above its signal line, a sign that short-term momentum is turning up.
The price has slipped below its 50-day moving average but is still above the 200-day: a pullback inside a longer-term uptrend.
Volume is only 0.5x its 20-day average; light trading makes the latest move less convincing.
Fundamentals
The PEG ratio is 1.47, which looks reasonably priced for its growth.
The company reports a profit margin of 9.7% and revenue growth of +14.5%.
In its latest quarter it earned $1.42 per share, which matched the $1.42 analysts expected.
Wall Street's average rating is 1.5 on a 1 (strong buy) to 5 (sell) scale, roughly a "buy", with an average price target of $118.52.
The next earnings report is expected around Jan 28, 2027; prices often move sharply around earnings.
Trade plan from the model
The model's long / bullish plan uses an entry near $102.64, a target of $106.75 (+4.0%) and a stop-loss at $96.56 (-5.9%).
That is a reward-to-risk ratio of about 0.7 to 1: the potential loss is bigger than the gain, a weak setup.
The plan has a time limit: reassess by Nov 8, 2026 whatever the price does.
The model's one-paragraph read
Leans BUY — composite score +0.18 (WEAK BUY). Technicals: RSI 63.21, MACD bullish, price below SMA50. Fundamentals: PEG 1.47, margin 9.7%, revenue growth 14.5%. Financial results: last EPS surprise +0.0%, next earnings 2027-01-28. FinGPT news read: positive. Memory: 2 prior look(s). Suggested levels: entry $102.64, target $106.75, stop-loss $96.56, exit by 2026-11-08 (10-calendar-day max hold (time-stop; reassess by this date regardless of P&L)).
Past ratings for ABT
| Date | Verdict | Confidence | Price | Move since | |
|---|---|---|---|---|---|
| Oct 29, 2026 | WEAK BUY | 18% | $102.64 | — | |
| Oct 14, 2026 | WEAK BUY | 26% | $102.61 | +0.0% | ✔ right direction |
"Move since" compares each call's price with the latest analysed price.
Recent news on ABT
- Oct 29, 2026: Abbott initiates pivotal trial for Cephea device, an innovative treatment for mitral heart valve disease (PR Newswire)
Other Healthcare stocks we cover
ALC · AMGN · AMRX · ANIP · ARWR · ASTH · ATEC · ATRC · AVAH · BCRX · BDX · BIIB
Frequently asked questions
Is ABT a buy right now?
As of Oct 29, 2026, our automated model rates Abbott Laboratories (ABT) WEAK BUY with 18% confidence: the signals lean positive, but they are mixed, so conviction is low. This is a model output for education, not personal investment advice.
What is the price target for ABT?
The model's most recent plan targets $106.75 with a stop-loss at $96.56, from an entry near $102.64.
When does Abbott Laboratories report earnings next?
The next earnings report is expected around Jan 28, 2027.
What does a WEAK BUY rating mean?
A WEAK BUY rating means the signals lean positive, but they are mixed, so conviction is low.
For information and education only. Not investment advice. Ratings are produced by an automated model, can be wrong, and may be out of date. Do your own research; you can lose money investing. The site's author may hold positions in stocks discussed here.